This is a WHO initative ·  Original source

Stigma is a significant contributor to poor physical and mental health in people with epilepsy and will not be improved with a single approach. A multipronged strategy, which is culturally appropriate, multisectoral and collaborative, is needed.

Misconceptions and poor understanding about the nature of epilepsy contribute to the burden of disease and lead to stigma. This includes the perception of epilepsy as a form of insanity, ruining people’s lives, and being untreatable or contagious. Misconceptions and negative attitudes cause people with epilepsy to feel shame, embarrassment and disgrace. The impact of feeling socially excluded contributes to the physical, psychological and social burden of epilepsy. Stigma can delay appropriate health care seeking, access to care, health financing and availability of treatment.

Institutionalized discrimination in epilepsy affects employment, education, marriage and childbearing, and driving regulations. Discriminatory laws exist in a number of countries. Most were repealed decades ago, but the legacy of these laws can still lead to misconceptions and discrimination.

Direct investments in health care do not necessarily lead to improvements in epilepsy-related stigma. To reduce stigma, funds need to be directed toward epilepsy awareness and stigma-reduction programmes. Policy-makers can reduce stigma by changing laws that are punitive to people with epilepsy.

The impact of feeling socially excluded contributes to the physical, psychological and social burden of epilepsy.

A multisectoral public health response needs to include interventions that improve the knowledge of individuals and their families, teachers, employers, health care providers, disability service providers, care providers, first responders, traditional healers, media, community and policy-makers.

Get to know more about the World Health Organization report: Epilepsy: a public health imperative

Leave a Reply

Open chat
Contact with us now
Chat with Anna
¡Hola! 👋🏻
Soy Anna, ¿en qué puedo ayudarte?

The user who fills in the information requested in this form declares to be entitled to do so and is solely responsible for the accuracy and completeness of the data and information entered, expressly exonerating MJN NEUROSERVEIS of any liability that may arise for this entity on the occasion of the information provided through this form.

Yes, I accept

L’usuari que complimenta la informació requerida al present formulari declara estar legitimat per això i es fa responsable exclusiu de la veracitat i integritat de les dades i informació que introdueix, exonerant expressament a MJN NEUROSERVEIS de qualsevol responsabilitat que es pugi generar per aquesta entitat amb ocasió de la informació facilitat a través del present formulari.

Si, accepto

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!

    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.


      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.